Cardiol Therapeutics Announces At-The-Market Equity Offering Program With Jefferies LLC

What happened

Cardiol Therapeutics entered into a sales agreement with Jefferies LLC for an at-the-market share offering of up to US$75 million. The company may sell common shares to the public from time to time at prevailing market prices on Nasdaq or other US trading markets, not in Canada.

Confirmed

Global impact / market context

Selling shares would bring cash into Cardiol that could support its operations or development work, but the article does not specify how funds would be used. New shares also increase the number of shares outstanding, which can reduce existing investors’ ownership percentage.

Analyst inference

The program sets a possible fundraising route, not a commitment to sell the full US$75 million. Because shares may be sold over time at prevailing prices, the amount raised and the reduction in existing shareholders’ ownership would depend on whether shares are sold and how many are issued.

Analyst inference

What to watch

1. Whether Cardiol begins selling shares under the agreement and how much it raises; US$75 million is the maximum available, not a stated fundraising target. Analyst inference
2. Any later disclosure of how the money raised will be used, since funding clinical development or company operations could change future spending needs and cash available. Analyst inference
3. How many shares are issued, which would reduce existing investors’ percentage ownership, and the timing and prices of sales in US markets. Analyst inference

Evidence

• Original source link unavailable